Objective:

The article examines the objective, findings, and clinical context described in Lonza to Acquire Five US CDMO Sites from Merck KGaA.

Approach:

• Transaction: Lonza agreed to acquire five US sites and associated businesses for a low- to mid-triple-digit-million Swiss franc amount. Closing is expected in mid-2027, subject to regulatory approval and customary conditions.
• Sites and capabilities: The sites are in St. Louis, Missouri; Madison and Verona, Wisconsin; Carlsbad, California; and Indianapolis, Indiana. Their capabilities include bioconjugation, high-potency payload-linkers, viral vectors, lipid nanoparticles, liposomes, PEGylated proteins, an…
• Workforce and operations: Approximately 1,100 employees are expected to transfer to Lonza. Its US CDMO workforce would exceed 6,000, and its US manufacturing sites would increase from four to nine.
• Merck portfolio: Merck KGaA said the divestment supports a focus on Life Science consumables, technologies, and services. Its BioReliance Contract Testing Services business is excluded and will remain with Merck.

Key Findings:

• The acquired sites are expected to generate approximately CHF250 million in sales in 2028.
• Lonza said the sites’ initial core EBITDA margin will be below the group average, with profitable growth expected as integration proceeds and existing capacity is used more fully.
• Further investment will depend on market demand.
• The businesses will operate independently until closing; the companies said customer programs and supply continuity will be priorities during the transition.

Interpretation:

Lonza said the acquisition will expand its US CDMO footprint and support products from clinical development through commercial manufacturing, including in antibody-drug conjugates and cell and gene therapies.

Limitations:

• The transaction remains subject to regulatory approval and other customary closing conditions.
• The source does not provide the exact purchase price.

Sources:

• Article context provided in the prompt